India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Thursday the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States following US FDA approval of its Abbreviated New Drug Application.
The product is bioequivalent to Azurity Pharmaceuticals Inc's Edarbii, and is indicated for the treatment of hypertension in adults to lower blood pressure.
Lupin says that it is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.
Azilsartan Medoxomil Tablets (RLD Edarbi) had estimated annual sales of USD53.5m in the US (IQVIA MAT April 2026)
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Upsher-Smith launches generic version of Ciprodex ear drop suspension
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market